ReviewEuropean journal of medical research2023
Role of telitacicept in the treatment of IgA nephropathy.
Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- Dual BAFF/APRIL inhibition with telitacicept in systemic lupus erythematosus and IgA nephropathy: pharmacological rationale, clinical efficacy, and safety on female fertility preservation.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Review
- Telitacicept for childhood HSPN: A prospective self-controlled study.Clinical rheumatology · 2026Article
- Review
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
- Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.Frontiers in immunology · 2026Observational
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.Frontiers in pediatrics · 2026Article
- Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study.BMC nephrology · 2025Article
- Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study.Pediatric rheumatology online journal · 2025Observational
- Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study.Clinical and experimental medicine · 2025Article
- Exploring Telitacicept for Neurological Autoimmune Disorders: A Case Study on Morvan Syndrome.The American journal of case reports · 2025Article
- Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.The American journal of case reports · 2025Article
- Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.Frontiers in medicine · 2025Article
- Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.Drug design, development and therapy · 2025Article
- Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.Frontiers in immunology · 2025Review
- Case Report: Telitacicept exposure in early pregnancy in a patient with SLE delivering an infant without any physical defect.Frontiers in medicine · 2025Article
- Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and up to 40% of patients with IgAN develop end-stage renal disease (ESRD). At present, an increasing amount of evidence indicates that the pathogenesis of IgAN is related to autoimmunity. In recent years, several studies have shown that B cell activating factors (BAFF), also known as B lymphocyte stimulators (BLyS), and proliferation-inducing ligand APRIL are extremely important for the activation of autoimmune signalling pathways, which have become key targets for the treatment of IgAN. As a dual-target biological agent, telitacicept can inhibit both BLyS and APRIL cytokines, improve the function of renal immune complexes, and reduce haematuria and proteinuria, which play important roles in IgAN pathogenesis and long-term prognosis. This article reviews the role of telitacicept in IgA nephropathy and discusses its potential for use in the treatment of IgAN and other autoimmune diseases where pathogenesis is driven by B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.